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Background
Cardiac involvement in patients with sarcoidosis is an
independent predictor of mortality and associated with
very poor prognosis. Inflammatory processes within the
myocardium as well as subsequent fibrotic myocardial
alterations may lead to diastolic dysfunction and at worst
sudden death resulting from ventricular tachy-arrhythmias
or conduction block. Diastolic dysfunction as a sign of left
ventricular (LV) impairment can be assessed accurately by
the measurement of early diastolic strain rate (EDSR). In
this follow up study we performed cardiovascular mag-
netic resonance (CMR) feature tracking (FT) in patients
with and without cardiac involvement of sarcoidosis in
order to investigate its impact on systolic and especially
diastolic function over time.
Methods
Patients with systemic sarcoidosis were consecultively
enrolled into the study. They underwent clinically routine
CMR exams on a 1.5 Tesla Philips INGENIA scanner.
CMR exams were classified as “cardiac involvement” if at
least one of the following pathologies occured: pathologi-
cal relative enhancement, late enhancement findings con-
sistent with (post-) inflammatory changes, myocardial
edema, pericardial effusion. Patients with cardiac involve-
ment underwent a follow up CMR exam within a time
frame of 36 ± 3,5 months. According to CMR results
patients were divided into 4 different groups (Gr.): group 1
(n = 14): patients with positive findings in both exams,
group 2 (n = 9): patients with positive findings only in the
initial exam; group 3 (n = 37): patients with sarcoidosis
but inconspicuous initial CMR exam and group 4 (n =
20): a control group of healthy age matched volunteers
with no medical history of sarcoidosis or cardiac disease.
In addition in each CMR exam FT derived systolic and
diastolic circumferential strain parameters were calculated
from SSFP-cine images in midventricular short axis, which
were acquired prior to contrast agent injection. Peak systo-
lic strain rate (PSSR), peak diastolic strain rate (PDSR),
Peak systolic circumferential strain (PSECC) as well as
early diastolic strain rate (EDSR) were calculated and com-
pared between groups. Patient characteristics are demon-
strated in table 1.
Results
EDSR in group1 patients was significantly lower (53,24 ±
15,26) compared to all other groups (Gr.2: 75,1 ± 22,62,
Gr.3: 77,25 ± 5,06, Gr.4: 79,74 ± 25,59 respecitvely; p <
0,05; table 1). Furthermore PSSR and PSECC were signifi-
cantly lower in group 1 in comparison to group 3 and 4
(p < 0,05; table 2). In both group 1 and 2 there was no
significant difference between initial CMR exam and
follow-up scan regarding PSSR, PDSR, PSECC or EDSR
(p > 0,05; table 3).
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Conclusions
This study reveals 2 major findings. First patients with
consistent cardiac involvement of sarcoidosis have a sig-
nificantly reduced EDSR. Second diastolic function in
patients with sarcoidosis and significantly impaired
EDSR is not likely to recover over time.
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PSSR PDSR PSECC EDSR Age (y) LVEF (%) LVEDV (ml) IVSD (mm)
Group1 (n= 14) -1,09 ± 0,75 1,14 ± 0,35 -18,43 ± 4,27 53,24 ± 15,26 50,57 ± 13,51 62,15 ± 8,87 120 ± 24,42 10,63 ± 1,66
Group2 (n = 9) -1,49 ± 0,37 1,42 ± 0,42 -22,21 ± 6,47 75,1 ± 22,62 51,89 ± 5,88 68,33 ± 7,75 106,33 ± 6 10,69 ± 1,69
Group3 (n = 37) -1,51 ± 0,39 1,36 ± 0,1 -24,33 ± 3,5 77,25 ± 5,06 50,78 ± 12,66 64,84 ± 4,76 116,53 ± 31,64 9,47 ± 1,62
Group4 (n = 20) -1,51 ± 0,28 1,37 ± 0,48 -24,53 ± 4,38 79,74 ± 25,59 59,32 ± 28,99 61,88 ± 7,07 135,99 ± 9,19 9,7 ± 1,84
Significance (p-value)
Group1 vs. Group2 0,1813 0,1153 0,1132 0,0133
Group1 vs. Group3 0,0105 0,1440 0,0010 0,0006
Group1 vs. Group4 0,0248 0,1347 0,0002 0,0014












Follow up Initial exam Follow up Significance (p-
value)
PSSR PDSR PSECC EDSR
Group1 (n=
14)
-1,09 ± 0,75 -1,4 ±
0,42













-1,49 ± 0,37 -1,4 ±
0,42




75,1 ± 22,62 75,62 ±
22,62
p > 0,05
FT results of group 1 and group 2 regarding initial exam and follow-up including 2-tailed t-test results.
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